AstraZeneca shares rose on Thursday after the drugmaker said it could face a fine of up to $4.5 million in China over ...

Reports Q4 revenue $14.89B, consensus $13.34B. The company said, “Our company delivered a very strong performance in 2024 with Total Revenue ...

TD Cowen analyst Steve Scala maintained a Buy rating on AstraZeneca (AZN – Research Report) today. The company’s shares closed yesterday at ...

Q4 2024 Management View CEO Pascal Soriot highlighted a strong 2024 performance with total revenue up 21% and core EPS growth at 19%, reflecting solid business momentum supported by pipeline ...

In substance and timing, AstraZeneca's decision to cancel a planned expansion of its flu vaccine facility at Speke is a blow to the government's recent zeal for growth. Instead of injecting £450m ...

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government. The investment, announced last year in the Tories' spring budget ...

LONDON, Jan 31 (Reuters) - AstraZeneca (AZN.L), opens new tab on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in northern England ...

LONDON — Pharmaceutical company AstraZeneca on Friday cancelled a planned 450 million-pound ($560 million) investment in a vaccine manufacturing plant in northwest England, blaming the new ...

AstraZeneca has abandoned a £450m investment in a major UK vaccine plant just days after Rachel Reeves vowed to “kick-start economic growth”. The drugmaker, which is Britain’s most valuable ...

BRITISH pharmaceutical giant AstraZeneca said on Friday (Jan 31) that it was abandoning plans to build a £450 million (S$756.9 million) vaccine plant, a major blow to the Labour government’s plans to ...

Confirming the reversal on Friday, a spokesperson for AstraZeneca said: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke. "Several factors ...

AstraZeneca has scrapped plans to invest £450m in expanding a vaccine manufacturing plant in Merseyside, blaming a reduction in government support. The pharmaceutical giant announced its decision ...